Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications
Author:
Affiliation:
1. Division of Oncology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA
2. Division of Oncology, Stanford University, Stanford, CA, USA
Abstract
Publisher
SAGE Publications
Subject
Oncology
Link
http://journals.sagepub.com/doi/pdf/10.1177/1758834015572284
Reference58 articles.
1. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
2. Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
3. Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
4. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
5. Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of Heterozygosity;Journal of the National Comprehensive Cancer Network;2023-07
2. Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia;Value in Health Regional Issues;2021-12
3. Quickly evolving near‐infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment;VIEW;2021-08-27
4. Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial;Contemporary Clinical Trials;2020-09
5. Trends in malignant melanoma mortality in 31 countries from 1985 to 2015*;British Journal of Dermatology;2020-04-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3